Medicinal composition with hemostatic function

A pharmaceutical composition and functional technology, applied in the field of pharmaceutical compositions with hemostatic function, can solve the problems of unstable conditions, life-threatening, vascular obstruction and the like, and achieve the effect of reducing the amount of bleeding

Inactive Publication Date: 2017-07-07
徐家祥
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this method is extremely unstable at the beginning of the reaction, and the reaction is often accompanied by a large amount of aggregation that causes the formation of spheroids, and the diameter of the aggregated spheroids is usually greater than 7 microns, which is likely to cause blood vessel obstruction and cause life-threatening

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition with hemostatic function

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Methods of microparticle formation without fibrinogen:

[0035] Put human albumin powder into 0.9% sodium chloride solution, and add a surfactant with a concentration of 0.05mg / ml-15mg / ml, such as tetradecyl sodium sulfate, Tween-80 or TritonX-151, to form a concentration Protein solution at 5-20% w / v. 2 ml of glutaraldehyde diluted in sodium chloride solution ranging from 0.01 to 3.0% was then added to a series of test tubes containing 2 ml of the above protein solution containing different concentrations of surfactant. After 10 minutes, add 10ml of ethanol [dilute to 80% (volume ratio) with water], and the solution will appear cloudy immediately. After another 10 minutes, dilute with 5 times the volume of sodium chloride solution to observe whether the suspension is clear, and the result is negative. Thereafter, the suspension was observed under a microscope at 1000 times, and it was found that the diameter of the particles in the suspension was less than 1 micron. ...

Embodiment 2

[0038] The method of linking fibrinogen to protein particles as tracer particles:

[0039] Using the same conditions as in Example 1, human albumin with a marker of 1-125 was used. The spheres were pelleted by centrifugation, and the number of radioactive protein particles contained in the pellet and the supernatant were measured, and it was found that 95% of the albumin particles formed spheres. If the solute of the solution is raised 2 times by the concentration of 0.9% sodium chloride solution, it becomes 1.8% sodium chloride solution or the 0.9% sodium chloride solution is reduced to 0.09% sodium chloride solution. The yield of spheroids was not greatly affected. If the pH of the buffer solution was lowered below 4, it was found that more alcohol was required for the formation of spheres than at pH 8, and pH below 4 slightly reduced the yield of spheres. decline.

Embodiment 3

[0041] Example 2 was repeated under the most preferred conditions, except that human albumin was coated with fluorescent isothiocyanate, and the optimal conditions of Example 1 were used, and the fibrinogen Added to the spheroid suspension, it was found that adding fibrinogen within fifteen minutes of spheroid formation stabilized the spheroids and gave the best mix. In addition, the sphere suspension must be further processed, including dilution, filtration, dialysis, re-filtration, centrifugation, electrophoresis separation, and column separation, which are completed after vacuum freeze-drying and reconstitution of frozen powder, among which Add or change buffers or preservatives during the process.

[0042] According to McGill et al.'s "Platelet cavity can reduce the bleeding time of platelet-deficient rabbits" on J.Lab.Clin.Med.1987,109:127-133, using platelet-deficient rabbits for pharmacological tests, 70mg The bleeding time of ten rabbits treated by the Busulfan method...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
osmolarityaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a medicinal composition with a hemostatic function. The medicinal composition comprises the following components: (A) 16-22wt% of double-layer spherical protein particles, (B) 0.8-2.3wt% of a surfactant, (C) 12-16wt% of a cross-linking agent and (D) 45-75wt% of a solvent, wherein the double-layer spherical protein particles contain human albumin spheres in the inner layer and fibrinogen bonded to the surfaces of the human albumin spheres through covalent bonds. The medicinal composition with the hemostatic function is suitable for intravenous injection, and in a suspension, the albumin spheres of which the surfaces are coated with the fibrinogen have the diameters being smaller than 1 micron and do not agglomerate, so that after intravenous injection, vascular obstruction is not caused and the promotion of wound healing and hemostasis is facilitated.

Description

technical field [0001] The invention relates to an operation hemostatic material, in particular to a medical composition with hemostatic function suitable for intravenous injection. Background technique [0002] As we all know, sufficient blood in the human body is the foundation of health. Many operations (such as cancer surgery) and medical treatment will cause blood loss, especially for patients with platelet deficiency, excessive blood loss may be life-threatening; Complex process. Therefore, there is an urgent need for a substance that is helpful to blood coagulation in the medical field, to shorten the hemostasis time, or to control the blood loss to a minimum. [0003] These clotting substances act like platelets and can reduce blood loss in patients after surgery and surgery and in patients with platelet deficiency; generally, such clotting substances must have surface molecules that allow them to participate in blood clotting, such as fibrinogen. Since such coagul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/38A61K47/64A61P7/04
CPCA61K9/0019A61K38/38
Inventor 徐家祥
Owner 徐家祥
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap